company background image
6535 logo

Lumosa Therapeutics TPEX:6535 Stock Report

Last Price

NT$196.50

Market Cap

NT$32.4b

7D

5.1%

1Y

193.3%

Updated

21 Dec, 2024

Data

Company Financials +

Lumosa Therapeutics Co., Ltd.

TPEX:6535 Stock Report

Market Cap: NT$32.4b

6535 Stock Overview

A clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. More details

6535 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 34.14% per year

Analysts in good agreement that stock price will rise by 20.8%

Risk Analysis

Highly volatile share price over the past 3 months compared to the TW market

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue (NT$38M)


My Notes

Capture your thoughts, links and company narrative

Lumosa Therapeutics Co., Ltd. Competitors

Center Laboratories

TPEX:4123

NT$29.9b

Bora Pharmaceuticals

TWSE:6472

NT$76.2b

TTY Biopharm

TPEX:4105

NT$18.1b

Synmosa Biopharma

TPEX:4114

NT$14.0b

Price History & Performance

Summary of share price highs, lows and changes for Lumosa Therapeutics
Historical stock prices
Current Share PriceNT$196.50
52 Week HighNT$400.00
52 Week LowNT$67.20
Beta0.47
1 Month Change-47.25%
3 Month Change-24.42%
1 Year Change193.28%
3 Year Change425.40%
5 Year Change486.57%
Change since IPO285.37%

Recent News & Updates

Recent updates

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Mar 10
Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24
We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Shareholder Returns

6535TW PharmaceuticalsTW Market
7D5.1%-0.01%-2.1%
1Y193.3%-2.7%25.6%

Return vs Industry: 6535 exceeded the TW Pharmaceuticals industry which returned -2.7% over the past year.

Return vs Market: 6535 exceeded the TW Market which returned 25.6% over the past year.

Price Volatility

Is 6535's price volatile compared to industry and market?
6535 volatility
6535 Average Weekly Movement11.7%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement4.4%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6535's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: 6535's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
200047n/awww.lumosa.com.tw

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology.

Lumosa Therapeutics Co., Ltd. Fundamentals Summary

How do Lumosa Therapeutics's earnings and revenue compare to its market cap?
6535 fundamental statistics
Market capNT$32.40b
Earnings (TTM)-NT$388.79m
Revenue (TTM)NT$37.82m

856.9x

P/S Ratio

-83.3x

P/E Ratio

Is 6535 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6535 income statement (TTM)
RevenueNT$37.82m
Cost of RevenueNT$13.96m
Gross ProfitNT$23.85m
Other ExpensesNT$412.65m
Earnings-NT$388.79m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.36
Gross Margin63.08%
Net Profit Margin-1,028.15%
Debt/Equity Ratio0%

How did 6535 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 05:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lumosa Therapeutics Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weiyu LiCapital Securities Corporation
Hsuan ChenKGI Securities Co. Ltd.
Hengyu FuMasterlink Securities Corp.